JANUVIA (sitagliptin), Merck's once-a-day oral treatment for patients with type 2 diabetes, has been granted a license from the European Commission. JANUVIA now becomes the first and only medication ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback